StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Gyre Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$12.82M, down 355.0% year over year. For fiscal 2025 it was $13.97M, down 21.1% from the year before. The highest annual figure on record is $17.71M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.97M-21.1%
FY2024Dec 31, 2024$17.71M–
FY2023Dec 31, 2023-$66.16M-742.9%
FY2022Dec 31, 2022$10.29M–
FY2021Dec 31, 2021-$87.60M–
FY2020Dec 31, 2020-$57.23M–
FY2019Dec 31, 2019-$57.13M–
FY2018Dec 31, 2018-$33.67M–
FY2017Dec 31, 2017-$21.65M–
FY2016Dec 31, 2016-$20.03M–
FY2015Dec 31, 2015-$13.33M–
FY2014Dec 31, 2014-$6.83M–
FY2013Dec 31, 2013-$9.15M–
FY2012Dec 31, 2012-$5.93M–
FY2011Dec 31, 2011-$7.27M-148.1%
FY2010Dec 31, 2010$15.11M–
FY2009Dec 31, 2009-$38.49M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$1.05M-145.3%
Q2 FY2026Jun 30, 2026-$12.88M–
Q1 FY2026Mar 31, 2026-$8.68M-409.2%
Q4 FY2025Dec 31, 2025$9.80M+770.3%
Q3 FY2025Sep 30, 2025$2.32M-50.4%
Q2 FY2025Jun 30, 2025-$1.23M-136.0%
Q1 FY2025Mar 31, 2025$2.81M-66.9%
Q4 FY2024Dec 31, 2024$1.13M–
Q3 FY2024Sep 30, 2024$4.68M-63.9%
Q2 FY2024Jun 30, 2024$3.42M-35.2%
Q1 FY2024Mar 31, 2024$8.49M+22.3%
Q4 FY2023Dec 31, 2023-$91.33M–
Q3 FY2023Sep 30, 2023$12.96M–
Q2 FY2023Jun 30, 2023$5.28M-89.8%
Q1 FY2023Mar 31, 2023$6.94M–
Q4 FY2022Dec 31, 2022-$21.59M–
Q3 FY2022Sep 30, 2022-$5.13M–
Q2 FY2022Jun 30, 2022$51.60M–
Q1 FY2022Mar 31, 2022-$14.59M–
Q4 FY2021Dec 31, 2021-$20.20M–
Q3 FY2021Sep 30, 2021-$25.14M–
Q2 FY2021Jun 30, 2021-$19.87M–
Q1 FY2021Mar 31, 2021-$22.39M–
Q4 FY2020Dec 31, 2020-$18.80M–
Q3 FY2020Sep 30, 2020-$16.06M–
Q2 FY2020Jun 30, 2020-$17.34M–
Q1 FY2020Mar 31, 2020-$5.04M–
Q4 FY2019Dec 31, 2019-$13.95M–
Q3 FY2019Sep 30, 2019-$13.16M–
Q2 FY2019Jun 30, 2019-$14.35M–
Q1 FY2019Mar 31, 2019-$15.67M–
Q4 FY2018Dec 31, 2018-$11.64M–
Q3 FY2018Sep 30, 2018-$8.31M–
Q2 FY2018Jun 30, 2018-$7.08M–
Q1 FY2018Mar 31, 2018-$6.65M–
Q4 FY2017Dec 31, 2017-$5.79M–
Q3 FY2017Sep 30, 2017-$5.84M–
Q2 FY2017Jun 30, 2017-$5.90M–
Q1 FY2017Mar 31, 2017-$4.12M–
Q4 FY2016Dec 31, 2016-$5.16M–

More Gyre Therapeutics figures

See a number that looks wrong?